At Vanderbilt Health in Nashville, researchers have developed a tool that answers one of cancer medicine's most frustrating questions: when an antibody drug fails, is it because the medicine can't reach the tumor, or because it doesn't work once it gets there? The answer, it turns out, matters enormously—and now there's a way to find out.
Single-cell spatial pharmacobiology, or SSP, is a new experimental platform created by Dr. Eben Rosenthal, chair of Otolaryngology–Head and Neck Surgery at Vanderbilt, alongside Guolan Lu, Ph.D., of Stanford University School of Medicine. Their work, published in Nature Biotechnology, reveals a hidden problem that has likely thwarted cancer treatments for years: the tumor's own architecture acts as a physical barrier, keeping life-saving drugs from reaching the cancer cells that need them most.
The challenge is real and widespread. Antibody-based therapies have revolutionized cancer treatment in many ways, yet they fail in a frustratingly high number of patients. Doctors haven't known whether these failures stem from poor drug delivery—the medicine simply can't penetrate deep enough into the tumor—or from the drug's insufficient biological activity once inside. It's a critical distinction that changes everything about how to design better treatments.
SSP changes this equation. The platform allows researchers to visualize exactly how drugs move through human solid tumors, which cells they interact with, how strongly they bind to their molecular targets, and how the tumor's microenvironment shapes their distribution and effectiveness. For the first time, clinicians can see the problem in granular detail.
The research revealed something striking: there's pronounced spatial heterogeneity in drug delivery across different tumor types. In simpler terms, some parts of the tumor get the drug while others don't. The culprit isn't the drug itself—it's the dense stromal architecture, the noncancerous tissue surrounding and infiltrating the tumor, which acts as an impenetrable fortress. This stromal barrier keeps therapeutic antibodies locked out, even when the drug is being administered directly into the patient's bloodstream.
Testing focused on panitumumab-IRDye800CW, an antibody being investigated in Phase 1 clinical trials for fluorescence-guided surgery. By directly measuring drug delivery at the site of treatment, SSP could distinguish tumor regions that are biologically unresponsive—meaning the drug doesn't work on those cells—from regions that are simply underexposed to the agent. This distinction opens new doors for treatment strategies.
"Current pharmacology tools and imaging methodologies do not provide the answers we need to understand which drugs fail due to poor delivery and which ones fail due to insufficient activity upon entering the tumor," Rosenthal explained. Now they do.
The implications ripple across oncology, particularly for notoriously difficult-to-treat cancers like pancreatic and head-and-neck tumors. If researchers can identify stromal barriers in individual patients, they can design combination therapies that both penetrate the tumor and activate the immune system more effectively. Rosenthal emphasized that additional studies with larger patient sample sizes could validate SSP's potential to transform how we identify and overcome barriers to drug efficacy—moving cancer treatment from guesswork toward precision medicine.